drug · small molecule
naltrexone ER
Marketedupdated 3mo agoby $AARD Aardvark Therapeutics, Inc.🔗 ChEMBL
Approvedcommunity read0 votes
🐶 often sniffed alongside
top 4Small molecule drug with a maximum clinical stage of Approval (across all indications), with 3 approved and 47 investigational indications.
targets
Opioid receptors; mu/kappa/delta
all catalysts(28)
approval · 28
Apr 13, 2006
approval
$ALKS49.47+0.53%
VIVITROL (NALTREXONE) — FDA approval
naltrexone ER
→
Oct 26, 2007
approval
$ALKS49.47+0.53%
VIVITROL (NALTREXONE) — FDA approval
naltrexone ER
→
Mar 22, 2010
approval
$ALKS49.47+0.53%
VIVITROL (NALTREXONE) — FDA approval
naltrexone ER
→
Mar 22, 2010
approval
$ALKS49.47+0.53%
VIVITROL (NALTREXONE) — FDA approval
naltrexone ER
→
Aug 18, 2010
approval
$ALKS49.47+0.53%
VIVITROL (NALTREXONE) — FDA approval
naltrexone ER
→
Oct 12, 2010
approval
$ALKS49.47+0.53%
VIVITROL (NALTREXONE) — FDA approval
naltrexone ER
→
Mar 28, 2013
approval
$ALKS49.47+0.53%
VIVITROL (NALTREXONE) — FDA approval
naltrexone ER
→
Jul 29, 2013
approval
$ALKS49.47+0.53%
VIVITROL (NALTREXONE) — FDA approval
naltrexone ER
→
Jul 29, 2013
approval
$ALKS49.47+0.53%
VIVITROL (NALTREXONE) — FDA approval
naltrexone ER
→
Jan 7, 2014
approval
$ALKS49.47+0.53%
VIVITROL (NALTREXONE) — FDA approval
naltrexone ER
→
Feb 9, 2014
approval
$ALKS49.47+0.53%
VIVITROL (NALTREXONE) — FDA approval
naltrexone ER
→
Apr 17, 2014
approval
$ALKS49.47+0.53%
VIVITROL (NALTREXONE) — FDA approval
naltrexone ER
→
Aug 29, 2014
approval
$ALKS49.47+0.53%
VIVITROL (NALTREXONE) — FDA approval
naltrexone ER
→
Jan 26, 2015
approval
$ALKS49.47+0.53%
VIVITROL (NALTREXONE) — FDA approval
naltrexone ER
→
Dec 8, 2015
approval
$ALKS49.47+0.53%
VIVITROL (NALTREXONE) — FDA approval
naltrexone ER
→
Jan 19, 2016
approval
$ALKS49.47+0.53%
VIVITROL (NALTREXONE) — FDA approval
naltrexone ER
→
May 19, 2016
approval
$ALKS49.47+0.53%
VIVITROL (NALTREXONE) — FDA approval
naltrexone ER
→
May 20, 2016
approval
$ALKS49.47+0.53%
VIVITROL (NALTREXONE) — FDA approval
naltrexone ER
→
Dec 9, 2016
approval
$ALKS49.47+0.53%
VIVITROL (NALTREXONE) — FDA approval
naltrexone ER
→
Dec 12, 2016
approval
$ALKS49.47+0.53%
VIVITROL (NALTREXONE) — FDA approval
naltrexone ER
→
Dec 28, 2018
approval
$ALKS49.47+0.53%
VIVITROL (NALTREXONE) — FDA approval
naltrexone ER
→
Jun 7, 2019
approval
$ALKS49.47+0.53%
VIVITROL (NALTREXONE) — FDA approval
naltrexone ER
→
Sep 6, 2019
approval
$ALKS49.47+0.53%
VIVITROL (NALTREXONE) — FDA approval
naltrexone ER
→
May 8, 2020
approval
$ALKS49.47+0.53%
VIVITROL (NALTREXONE) — FDA approval
naltrexone ER
→
Mar 4, 2021
approval
$ALKS49.47+0.53%
VIVITROL (NALTREXONE) — FDA approval
naltrexone ER
→
May 6, 2021
approval
$ALKS49.47+0.53%
VIVITROL (NALTREXONE) — FDA approval
naltrexone ER
→
Sep 30, 2022
approval
$ALKS49.47+0.53%
VIVITROL (NALTREXONE) — FDA approval
naltrexone ER
→
Dec 22, 2025
approval
$ALKS49.47+0.53%
VIVITROL (NALTREXONE) — FDA approval
naltrexone ER
→
Trials studying naltrexone ER
- phase4A Randomized Controlled Trial Comparing the Effectiveness of Different Treatment Options for Weight Management After Discontinuation of Semaglutide and Tirzepatide (GLP1 Transition Trial)
- phase4Effect of Naltrexone Hydrochloride ER and Bupropion Hydrochloride ER Combination (Contrave®/Mysimba®) on Major Adverse Cardiovascular Events (MACE)
- phase3Combination Gerotherapeutic Interventions for Healthspan Improvement
- phase3Evaluate the Efficacy and Safety of Naltrexone Hydrochloride Implant in Patients With Alcohol Use Disorder
- phase2Evaluation of the O'Neil Long Acting Naltrexone Implant in Opioid Dependent Persons
- phase1iSTEP-N 101b: Pharmacokinetics and Safety Study of Low- and High-Dose Naltrexone Implants vs Monthly Vivitrol in Healthy Volunteers
- phase4A Research Study Comparing Wegovy to Other Weight Management Drugs in People Living With Obesity in America
- phase2Phase II Clinical Study on the Efficacy and Safety of Naltrexone Implant in Patients With Alcohol Use Disorder
Patent cliff
source: FDA Orange Bookfirst barrier falls
Oct 15, 2029
~3.2 years out
Earliest of all listed patents + FDA exclusivities. Generic / biosimilar entry typically only becomes possible AFTER both patent and exclusivity barriers expire.
patents (1)
- Oct 15, 2029method-of-use (U-1123)US 79194993.2y
News(4)
- 4 potential biotech M&A targets, plus a pretty sure bet from J&JPharma is definitely interested in making more deals. But what biotechs will come under the magnifying glass? BioSpace takes a look at companies that analysts see as near-term targets for buyouts.biospace · 7d ago
- 12 ideas for tackling the U.S. alcohol epidemicThe U.S. can save lives from excess alcohol use without taking drastic measures. Here are 12 steps that can help.stat · 29d ago
- Alkermes’ incoming CEO has a plan to outplay Lilly and TakedaBlair Jackson says the next 12 months may be the most important in Alkermes’ history, as the brain drugmaker races to join an “orexin” market that analysts see as a multibillion-dollar opportunity.biopharma_dive · 1mo ago
- Are Republicans turning against medications for treating opioid addiction?Federal actions and proposals have reignited debate over methadone and buprenorphine, worrying addiction experts and patient groups.stat · 2mo ago
Data sources
last refreshed 1h ago
Found something off?
comments(0)
5-min edit window · permanent after that